BACKGROUND	In a randomized phase II study in patients with renal cell carcinoma , 10 microg/kg bevacizumab ( Avastin ; Genentech , Inc. , South San Francisco , CA ) administered every 2 weeks resulted in a longer time to progression but a statistically significant difference in overall survival could not be demonstrated .\